Cargando…
Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy
BACKGROUND: While initiation of highly active antiretroviral therapy (HAART) during primary HIV-1 infection occasionally results in transient control of viral replication after treatment interruption, the vast majority of patients eventually experience a rebound in plasma viremia. RESULTS: Here we r...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3293762/ https://www.ncbi.nlm.nih.gov/pubmed/22141397 http://dx.doi.org/10.1186/1742-4690-8-97 |
_version_ | 1782225417010151424 |
---|---|
author | Salgado, Maria Rabi, S Alireza O'Connell, Karen A Buckheit III, Robert W Bailey, Justin R Chaudhry, Amina A Breaud, Autumn R Marzinke, Mark A Clarke, William Margolick, Joseph B Siliciano, Robert F Blankson, Joel N |
author_facet | Salgado, Maria Rabi, S Alireza O'Connell, Karen A Buckheit III, Robert W Bailey, Justin R Chaudhry, Amina A Breaud, Autumn R Marzinke, Mark A Clarke, William Margolick, Joseph B Siliciano, Robert F Blankson, Joel N |
author_sort | Salgado, Maria |
collection | PubMed |
description | BACKGROUND: While initiation of highly active antiretroviral therapy (HAART) during primary HIV-1 infection occasionally results in transient control of viral replication after treatment interruption, the vast majority of patients eventually experience a rebound in plasma viremia. RESULTS: Here we report a case of a patient who was started on HAART during symptomatic primary infection and who has subsequently maintained viral loads of < 50 copies/mL for more than nine years after the cessation of treatment. This patient had a high baseline viral load and has maintained a relatively high frequency of latently infected CD4(+ )T cells. In addition, he does not have any known protective HLA alleles. Thus it is unlikely that he was destined to become a natural elite controller or suppressor. The mechanism of control of viral replication is unclear; he is infected with a CCR5/CXCR4 dual-tropic virus that is fully replication-competent in vitro. In addition, his spouse, who transmitted the virus to him, developed AIDS. The patient's CD4(+ )T cells are fully susceptible to HIV-1 infection, and he has low titers of neutralizing antibodies to heterologous and autologous HIV-1 isolates. Furthermore, his CD8(+ )T cells do not have potent HIV suppressive activity. CONCLUSION: This report suggests that some patients may be capable of controlling pathogenic HIV-1 isolates for extended periods of time after the cessation of HAART through a mechanism that is distinct from the potent cytotoxic T lymphocyte (CTL) mediated suppression that has been reported in many elite suppressors. |
format | Online Article Text |
id | pubmed-3293762 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-32937622012-03-06 Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy Salgado, Maria Rabi, S Alireza O'Connell, Karen A Buckheit III, Robert W Bailey, Justin R Chaudhry, Amina A Breaud, Autumn R Marzinke, Mark A Clarke, William Margolick, Joseph B Siliciano, Robert F Blankson, Joel N Retrovirology Research BACKGROUND: While initiation of highly active antiretroviral therapy (HAART) during primary HIV-1 infection occasionally results in transient control of viral replication after treatment interruption, the vast majority of patients eventually experience a rebound in plasma viremia. RESULTS: Here we report a case of a patient who was started on HAART during symptomatic primary infection and who has subsequently maintained viral loads of < 50 copies/mL for more than nine years after the cessation of treatment. This patient had a high baseline viral load and has maintained a relatively high frequency of latently infected CD4(+ )T cells. In addition, he does not have any known protective HLA alleles. Thus it is unlikely that he was destined to become a natural elite controller or suppressor. The mechanism of control of viral replication is unclear; he is infected with a CCR5/CXCR4 dual-tropic virus that is fully replication-competent in vitro. In addition, his spouse, who transmitted the virus to him, developed AIDS. The patient's CD4(+ )T cells are fully susceptible to HIV-1 infection, and he has low titers of neutralizing antibodies to heterologous and autologous HIV-1 isolates. Furthermore, his CD8(+ )T cells do not have potent HIV suppressive activity. CONCLUSION: This report suggests that some patients may be capable of controlling pathogenic HIV-1 isolates for extended periods of time after the cessation of HAART through a mechanism that is distinct from the potent cytotoxic T lymphocyte (CTL) mediated suppression that has been reported in many elite suppressors. BioMed Central 2011-12-05 /pmc/articles/PMC3293762/ /pubmed/22141397 http://dx.doi.org/10.1186/1742-4690-8-97 Text en Copyright ©2011 Salgado et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Salgado, Maria Rabi, S Alireza O'Connell, Karen A Buckheit III, Robert W Bailey, Justin R Chaudhry, Amina A Breaud, Autumn R Marzinke, Mark A Clarke, William Margolick, Joseph B Siliciano, Robert F Blankson, Joel N Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy |
title | Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy |
title_full | Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy |
title_fullStr | Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy |
title_full_unstemmed | Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy |
title_short | Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy |
title_sort | prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3293762/ https://www.ncbi.nlm.nih.gov/pubmed/22141397 http://dx.doi.org/10.1186/1742-4690-8-97 |
work_keys_str_mv | AT salgadomaria prolongedcontrolofreplicationcompetentdualtropichumanimmunodeficiencyvirus1followingcessationofhighlyactiveantiretroviraltherapy AT rabisalireza prolongedcontrolofreplicationcompetentdualtropichumanimmunodeficiencyvirus1followingcessationofhighlyactiveantiretroviraltherapy AT oconnellkarena prolongedcontrolofreplicationcompetentdualtropichumanimmunodeficiencyvirus1followingcessationofhighlyactiveantiretroviraltherapy AT buckheitiiirobertw prolongedcontrolofreplicationcompetentdualtropichumanimmunodeficiencyvirus1followingcessationofhighlyactiveantiretroviraltherapy AT baileyjustinr prolongedcontrolofreplicationcompetentdualtropichumanimmunodeficiencyvirus1followingcessationofhighlyactiveantiretroviraltherapy AT chaudhryaminaa prolongedcontrolofreplicationcompetentdualtropichumanimmunodeficiencyvirus1followingcessationofhighlyactiveantiretroviraltherapy AT breaudautumnr prolongedcontrolofreplicationcompetentdualtropichumanimmunodeficiencyvirus1followingcessationofhighlyactiveantiretroviraltherapy AT marzinkemarka prolongedcontrolofreplicationcompetentdualtropichumanimmunodeficiencyvirus1followingcessationofhighlyactiveantiretroviraltherapy AT clarkewilliam prolongedcontrolofreplicationcompetentdualtropichumanimmunodeficiencyvirus1followingcessationofhighlyactiveantiretroviraltherapy AT margolickjosephb prolongedcontrolofreplicationcompetentdualtropichumanimmunodeficiencyvirus1followingcessationofhighlyactiveantiretroviraltherapy AT silicianorobertf prolongedcontrolofreplicationcompetentdualtropichumanimmunodeficiencyvirus1followingcessationofhighlyactiveantiretroviraltherapy AT blanksonjoeln prolongedcontrolofreplicationcompetentdualtropichumanimmunodeficiencyvirus1followingcessationofhighlyactiveantiretroviraltherapy |